Legal Path for Investors: Join the Class Action Against Applied Therapeutics
Bronstein, Gewirtz & Grossman LLC, a well-known law firm with a national presence, has announced an opportunity for investors who have suffered losses in Applied Therapeutics, Inc. This class action lawsuit has been initiated to hold the company accountable for alleged violations of federal securities laws. If you purchased or acquired shares of Applied Therapeutics between January 3, 2024, and December 2, 2024, you may be eligible to participate in this legal action.
Understanding the Class Action Lawsuit
The lawsuit aims to recover damages for investors who might have been misled by erroneous statements regarding the company's new drug application for govorestat. The allegations suggest that the company's executives made misleading claims about the drug’s potential approval by the FDA. Key points of the complaint state that the New Drug Application for govorestat had serious deficiencies, which were not disclosed to investors. Furthermore, the clinical data supporting this application was insufficient to prove either efficacy or safety, thus invalidating previous positive statements made about the approval chances.
This situation has raised significant concerns among stakeholders who trusted the company's optimistic outlook. Investors who feel aggrieved must act promptly, as they have until February 18, 2025, to petition the court for appointment as lead plaintiffs in the case. While the opportunity to lead the class action exists, it's crucial to note that joining the lawsuit does not require being the lead plaintiff, and all investors are encouraged to participate to advocate for their rights.
How to Get Involved
Interested investors can easily initiate their involvement by visiting the law firm’s website at
bgandg.com/APLT, where they can review details of the complaint and understand their legal standing. For specific inquiries or personalized guidance, potential plaintiffs are welcome to reach out directly to Peretz Bronstein or Client Relations Manager Nathan Miller at Bronstein, Gewirtz & Grossman, LLC.
The law firm operates on a contingency fee basis, ensuring that representation is available without any upfront charges for the clients. If successful, they will seek reimbursement for legal fees and other costs from the recovery total. This model allows investors to pursue justice without the burden of immediate financial pressure.
Why Choose Bronstein, Gewirtz & Grossman?
Bronstein, Gewirtz & Grossman has a long-standing reputation for supporting investors in class actions and has successfully recouped hundreds of millions of dollars for clients nationwide. Their expertise in securities fraud and shareholder derivative lawsuits positions them as a formidable advocate for investors seeking justice against corporations that mislead their shareholders.
In conclusion, if you have been affected by the alleged misrepresentations made by Applied Therapeutics regarding its drug approval process, now is the time to consider your options within this class action lawsuit. Participation not only provides a path for potential recovery but also empowers investors to stand up against corporate malfeasance.
Stay updated with industry developments by following Bronstein, Gewirtz & Grossman on social media platforms like LinkedIn, X, Facebook, or Instagram.